Cytomegalovirus disease following liver transplantation: An analysis of prophylaxis strategies

Journal of Infection

Volumn 47, Issue 2, 2003, Pages 104-109

  Singhal, S ^a   Khan, Omar A ^a   Bramble, R A ^a   Mutimer, D J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Cytomegalovirus; Ganciclovir; Liver transplant; Prophylaxis

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID; TACROLIMUS;

AGE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG INDICATION; DRUG USE; DRUG WITHDRAWAL; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NEUTROPENIA; PATIENT SELECTION; RECIPIENT; RETROSPECTIVE STUDY; TIME; TREATMENT PLANNING;

EID: 0041811776     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(03)00018-5     Document Type: Article

References (12)

1. O'Grady JG, Alexander GJ, Sutherland S, Donaldson PT, Harvey F, Portmann B, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988;II(8606):302-305.
2. Falagas ME, Paya C, Ruthazer R, Badley A, Patel R, Wiesner R, et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 1998;66:1020-1028.
3. Falagas ME, Arbo M, Ruthazer R, Griffith JL, Werner BG, Rohrer R, et al. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients. Transplantation 1997;63: 1595-1601.
4. Whiting JF, Martin J, Zavala E, Hanto D. The influence of clinical variables on hospital costs after orthotopic liver transplantation. Surgery 1999;125:217-222.
5. Paya CV, Wiesner RH, Hermans PE, Larson-Keller JJ, Ilstrup DM, Krom RA, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. Journal of Hepatology 1993;18:185-195.
6. Gorensek MJ, Carey WD, Vogt D, Goormastic M. A multivariate analysis of risk-factors for cytomegalovirus infection in liver-transplant recipients. Gastroenterology 1990;98:1326-1332.
7. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995;346:69-74.
8. Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovitz MD, Lyman S, et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-1733.
9. Kusne S, Grossi P, Irish W, St George K, Rinaldo C, Rakela J, et al. Cytomegalovirus PP65 antigenaemia monitoring as a guide for pre-emptive therapy: a cost-effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1999;68:1125-1131.
10. Koopmanschap MA, Lubbe KT, van Oortmarssen GJ, van Agt HM, van Ballegooijen M, Habbema JK. Economic aspects of cervical cancer screening. Social Science and Medicine 1990; 30:1081-1087.
11. Jonsson B, Johanneson M, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). European Heart Journal 1996;17:1001-1007.
12. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356:645-649.